[Unveiling antigens in a non-immunogenic spontaneous murine tumor using a dendritic cell based vaccine].
Up to date, most attempts to use immunotherapy to cause the regression of animal and human established tumors have not been successful. Former experiments have postulated that this failure could be attributed, at least in part, to a lack of immunogenicity of spontaneous tumors. In this paper, we have investigated whether this lack of immunogenicity can be attributed to the absence of tumor antigens or to the existence of tolerogenic mechanisms preventing such antigens from initiating an antitumor immune response. We have used two murine tumors a non-immunogenic spontaneous lymphoma (LB) and a strongly immunogenic methylcholanthrene-induced fibrosarcoma (MC-C) together with a vaccination strategy based on the inoculation of dendritic cells (DC) loaded with a tumor lysate. When DC were pulsed with LB lysate (DC+LB), no maturation of DC was achieved in vitro and no protection against LB implants after DC+LB inoculation was observed in vivo. On the other hand, when DC were pulsed with MC-C lysate (DC+MC-C), maturation of DC was observed along with a strong protection against MC-C implants after DC+MC-C inoculaton. Finally, when DC were pulsed with both LB and MC-C lysates (DC+LB+MC-C), maturation of DC and protection against LB implants were achieved. Since no immune cross reaction between MC-C and LB was ever observed, the most likely interpretation is that LB bears specific tumor antigens but lacks other signals to achieve DC maturation. These signals would be provided by MC-C which would enable DC to mature and to initiate an effective anti-LB immune response.
Reffo
Verónica L
VL
División Medicina Experimental, ILEX-CONICET, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina, Buenos Aires.
Chiarella
Paula
P
Bruzzo
Juan
J
Bustuoabad
Oscar D
OD
Ruggiero
Raúl A
RA
D000818:Animals; D000951:Antigens, Neoplasm / Q000276:immunology*; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines / Q000276:immunology* / Q000627:therapeutic use; D003713:Dendritic Cells / Q000276:immunology*; D004195:Disease Models, Animal; D005354:Fibrosarcoma / Q000139:chemically induced / Q000276:immunology*; D007167:Immunotherapy / Q000379:methods; D016393:Lymphoma, B-Cell / Q000139:chemically induced / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines